REG - Surgical Innovations - Product launch in partnership with CMR Surgical

Surgical InnovationsAnnouncement

21/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220321:nRSU3419Fa&default-theme=true

RNS Number : 3419F  Surgical Innovations Group PLC  21 March 2022

 

Surgical Innovations Group plc

("Surgical Innovations", "SI" or the "Company")

 

Product launch in partnership with CMR Surgical

Design agreement secured for a new surgical Resposable™ Port Access System

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and
distributor of innovative medical technology for minimally invasive surgery
("MIS"), announces the launch of YelloPort™ Elite 5mm, a new surgical Port
Access System, developed in partnership with CMR Surgical ('CMR'), a global
medical devices company dedicated to transforming surgery with Versius®, a
next-generation surgical robot. Under the design agreement Surgical
Innovations and CMR have signed, the Company will supply the Resposable(TM)
item for each installed CMR Surgical's Versius Robotic System(â).

 

The new YelloPort Elite™ 5mm product was designed specifically for CMR
Surgical's Versius Robotic System(â), though it is universal in nature and
can be used in combination with a wider range of laparoscopic instrumentation
including other robotic systems. The device is designed to function
effectively with robotic instrumentation and addresses the continuing need for
high-quality cost-effective solutions within laparoscopy surgery, utilising
the Company's Resposable(TM) technology to meet these clinical needs.
YelloPort Elite™ 5mm received its CE mark in February 2022 and will be
available globally from April 2022.

 

This is the first project that Surgical Innovations and CMR Surgical, two
British-based medical device companies, have collaborated on. Both target
international healthcare markets.

 

Mark Slack, Chief Medical Officer, CMR Surgical, said: "When we talk to
hospitals and clinical teams, we hear how important it is for them to reduce
the environmental impact of the surgical products and instruments they use. We
want to partner with hospitals to reduce waste and cost, whilst advancing
performance. Working with Surgical Innovations to develop this new port, for
use with our robotic systems, we've been able to do just that."

 

David Marsh, Chief Executive Officer of Surgical Innovations, said: "We're
delighted to partner with CMR Surgical, a fellow British medical device
company focused in minimally invasive surgery, to develop this new surgical
Port Access System. Our Resposable(TM) products provide a high-quality hybrid
instrument concept, with the clinical benefits of a small disposable element,
reducing waste by at least 70% compared to fully disposable alternatives. The
project with CMR also creates opportunity to develop greater partnerships in
robotic surgery and utilises our existing experience in access devices,
instrumentation and flex technology."

 

 

For further information please contact:
 
 Surgical Innovations Group plc                    www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                  Tel: 0113 230 7597
 Charmaine Day, CFO

 Singer Capital Markets (Nominated Adviser & Broker)                                                    Tel: 020 7496 3000
 Aubrey Powell / Rachel Hayes / Michael Nothnagel

 Walbrook PR (Financial PR & Investor Relations)                               Tel: 020 7933 8780 or
                                                                               si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Lianne Applegarth                  Mob: 07980 541 893 / 07584 391 303

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of
innovative, high quality medical products, primarily for use in minimally
invasive surgery. Our product and business development is guided and supported
by a key group of nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical
instruments and retraction devices which are sold directly in the UK home
market through our subsidiary, Elemental Healthcare, and exported widely
through a global network of trusted distribution partners. Many of our
products in this field are based on a "resposable" concept, in which the
products are part reusable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive against
fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist
products employed in laparoscopy, bariatric and metabolic surgery, hernia
repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also
collaborated with a major UK industrial partner to provide precision engineering solutions to complex
problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare
professionals in all major geographical markets in which we operate and
provide by development, partnership or acquisition a
broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that
offer reliable solutions to genuine clinical needs in the operating
theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the
following websites:

www.sigroupplc.com (http://www.sigroupplc.com)

www.surginno.com (http://www.surginno.com)

www.elementalhealthcare.co.uk (http://www.elementalhealthcare.co.uk)

 

To receive regular updates by email, please contact si@walbrookpr.com
(mailto:si@walbrookpr.com)

 

About CMR Surgical Limited |
www.cmrsurgical.com (http://www.cmrsurgical.com/)
 

CMR Surgical (CMR) is a global medical devices company dedicated to
transforming surgery with Versius(®), a next-generation surgical robot.

 

Headquartered in Cambridge, United Kingdom, CMR is committed to working with
surgeons, surgical teams and hospital partners, to provide an optimal tool to
make robotic minimal access surgery universally accessible and affordable.
With Versius, we are on a mission to redefine the surgical robotics market
with practical, innovative technology and data that can improve surgical care.

 

Founded in 2014, CMR Surgical is private limited company backed by an
international shareholder base.

 

About the Versius(®) Surgical Robotic System

Versius(®) resets expectations of robotic surgery. Versius fits into
virtually any operating room set-up and integrates seamlessly into existing
workflows, increasing the likelihood of robotic minimal access surgery (MAS).
The small, portable and modular design of Versius allows the surgeon to only
use the number of arms needed for a given procedure.

 

Biomimicking the human arm, Versius gives surgeons the choice of optimised
port placement alongside the dexterity and accuracy of small fully-wristed
instruments. With 3D HD vision, easy-to adopt instrument control and a choice
of ergonomic working positions, the open surgeon console has the potential to
reduce stress and fatigue and allows for clear communication with the surgical
team. By thinking laparoscopically and operating robotically with Versius,
patients, surgeons and healthcare professionals can all benefit from the value
that robotic MAS brings.

 

Versius also captures meaningful data with its wider digital ecosystem to
support a surgeon's continuous learning. Through the Versius Connect app,
Versius Trainer and CMR clinical registry, the Versius system unleashes can
generate a wealth of insights with the ultimate goal of supporting
improvements in surgical care.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLGZGMFNRNGZZM